卫信康(603676) - 卫信康投资者关系活动记录表（2024-04-30）

Group 1: Company Overview - The company is West China Weixin Kang Pharmaceutical Co., Ltd. with stock code 603676 [1] - The board secretary introduced the basic situation of the company [3] Group 2: Sales and Market Performance - As of now, 15 provinces have officially executed the selected results for injectable multivitamins (12) [3] - The company has completed hospital coverage for over 370 hospitals for the pediatric multivitamin injection (13) [4] - The sales situation may be influenced by market environment changes and other factors [3] Group 3: Product and Regulatory Updates - The 2023 National Medical Insurance Directory has lifted payment restrictions on two products, potentially benefiting more patients [3] - The company plans to focus on promoting the adult 13 kinds of compound vitamin injections for inclusion in the medical insurance directory [4] Group 4: Financial Performance - The gross profit margin increased in Q1 2024 due to a reduction in service costs [4] - The company invested 114 million yuan in R&D in 2023, a 42.55% increase year-on-year [4] Group 5: Future Strategies - The company is actively developing new differentiated fields through the newly established Nanjing laboratory [4] - The company is focusing on the health industry, particularly in niche areas and products [4] Group 6: Pricing Governance - The company has ensured compliance with the "Four Same" pricing governance requirements, which aim to eliminate unfair pricing by March 2024 [5]